Five-year outcomes in trials comparing transcatheter aortic valve implantation versus surgical aortic valve replacement: a pooled meta-analysis of reconstructed time-to-event data. (16th December 2021)

• Record Type: Journal Article
• Authors: Barili, Fabio; Freemantle, Nicholas; Musumeci, Francesco; Martin, Barbara; Anselmi, Amedeo; Rinaldi, Mauro; Kaul, Sanjay; Rodriguez-Roda, Jorge; Di Mauro, Michele; Folliguet, Thierry; Verhoye, Jean-Philippe; Sousa-Uva, Miguel; Parolari, Alessandro
• Is Part Of: European journal of cardio-thoracic surgery. Volume 61:Number 5(2022)
• Page Start: 977
• Page End: 987
• Publication Date: 2021-12-16
• Subjects: Transcatheter aortic valve replacement -- Surgical aortic valve replacement -- Follow-up -- Aortic valve stenosis; Heart -- Surgery -- Periodicals; Chest -- Surgery -- Periodicals; 617.54
• DOI: 10.1093/ejcts/ezab516
• Languages: English
• ISSNs: 1010-7940

Abstract

Abstract: OBJECTIVES: The incidence of outcomes in trials comparing transcatheter aortic valve implantation (TAVI) and surgical aortic valve replacement (SAVR) is expected to be different in the short and long term. We planned a meta-analysis of reconstructed time-to-event data from trials comparing TAVI and SAVR to evaluate their time-varying effects on outcomes. METHODS: We performed a systematic review of the literature from January 2007 through September 2021 on Medline, Embase, the Cochrane Central Register of Controlled Trials and specialistic websites, including randomized trials with allocation to TAVI or SAVR that reported at least 1-year follow-up and that graphed Kaplan–Meier curves of end points. The comparisons were done with grouped frailty Cox models in a landmark framework and fully parametric models. RESULTS: Seven trials were included (7770 participants). TAVI showed a lower incidence of the composite of death or stroke in the first 6 months [risk-stratified hazard ratio (HR) 0.66, 95% confidence interval (CI) 0.56–0.77, P -value <0.001], with an HR reversal after 24 months favouring SAVR (risk-stratified HR 1.25; 95% CI 1.08–1.46; P -value 0.003). These outcomes were confirmed for all-cause death (risk-stratified HR after 24 months 1.18; 95% CI 1.03–1.35; P -value 0.01). TAVI was also associated with an increased incidence of rehospitalization after 6 months (risk-stratified HR 1.42; 95% CI 1.06–1.91; P -value 0.018) that got worse after 24 months (risk-stratified HR 1.67; 95% CI 1.24–2.24; P -value <0.001). CONCLUSIONS: Although it could appear that there is no difference between TAVI and SAVR in the 5-year cumulative results, TAVI shows a strong protective effect in the short term that runs out after 1 year. TAVI becomes a risk factor for all-cause mortality and the composite end point after 24 months and for rehospitalization after 6 months. Abstract : Transcatheter aortic valve implantation (TAVI) has been recognized as the primary choice for the treatment of aortic valve stenosis in prohibitive-risk and high-risk patients and as an alternative to surgery in intermediate-risk patients [1–3].